BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317
BEIJING, Sept. 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has …